Tag: Securities and Exchange Commission

OTTAWA, Ontario, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Telesat (Nasdaq and TSX: TSAT), one of the world’s largest and most innovative satellite operators, today announced its financial results for the three and six-month periods ended June 30, 2025. All amounts are in Canadian dollars and reported under IFRS^® Accounting Standards unless otherwise noted.

Q2 2025 Financial Highlights

For the three months ended June 30, 2025, from continuing operations:

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that the Company’s board of directors has approved the consolidation (the “Consolidation”) of the Company’s issued and outstanding common shares (the “Common Shares”) on the basis of one (1) post-Consolidation Common Share for every ten (10) pre-Consolidation Common Shares. The Consolidation is being implemented to ensure that the Company continues to comply with the listing requirements of The Nasdaq Capital Market (the “Nasdaq”).

SAN FRANCISCO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Investors in Simulations Plus, Inc. (NASDAQ: SLP) saw the price of their shares decline about 25% on July 15, 2025 after the company reported its Q3 2025 $67.3 million net loss that included a $77.2 million impairment charge and the company’s firing of its independent auditor Grant Thornton, whom it hired on April 15, 2025.

VERO BEACH, Florida, Aug. 05, 2025 (GLOBE NEWSWIRE) -- ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) (“ARMOUR” or the “Company”) today announced that it is commencing an underwritten public offering of 18,500,000 shares of common stock. ARMOUR expects to grant the underwriters a 30-day option to purchase up to 2,775,000 additional shares of its common stock.

MELVILLE, N.Y., Aug. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its second quarter 2025 financial results after market close on Tuesday, August 12, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update.

Reaffirms 2025 Sales and Earnings Guidance